India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
Scrub typhus: a growing health challenge in children Recently, an 11-year-old girl was admitted to Rapti Institute of Health Sciences in Dang due to high fever and physical weakness. Initially, he was treated for a simple fever, but after a few days, his condition worsened. On further examination, it was discovered that he had scrub typhus. In the absence of timely treatment, the disease seriously affected his liver, kidneys, and lungs, resulting in multi-organ failure. The girl was kept on a ventilator, although various life-saving measures were taken, but it became a challenge to improve her health. In the last few years, there has been a significant increase in the incidence of scrub typhus in Nepal. Scrub typhus is a type of bacterial disease that is spread by insects (chiggers) found in wooded areas infected with the bacterium Orientia tsutsugamushi. In children, this disease can cause serious health problems, as evidenced by a recent complex case of multi-organ failure in an...